Skip to content

    Rossari Biotech

    ROSSARIGood
    Chemicals·23 Jan 2025
    Management Summary

    Rossari Biotech delivered a resilient performance in Q3 FY25, driven primarily by strong export growth across all segments, despite softer domestic market conditions. While gross margins improved, EBITDA margins were impacted by higher expenses related to ongoing growth initiatives and capacity expansion. The company is making steady progress on new capacity commissioning, though potential delays in Ethylene Oxide supply from Reliance pose a risk to future utilization and profitability.

    Highlights

    8
    • Consolidated revenues increased by 10.5% YoY to ₹512.7 crore.

    • EBITDA stood at ₹64.8 crore, with EBITDA margin at 12.6% (vs 13.7% in Q3 FY24).

    • PAT for the quarter was ₹31.7 crore.

    • Gross margin improved by 137 bps YoY.

    • Exports registered strong double-digit growth of 21% YoY in Q3, reaching ₹156 crore.

    • HPPC division revenue grew 9.6% YoY to ₹390 crore.

    • Textile Specialty Chemical division revenue grew 14.5% YoY to ₹95 crore.

    • AHN division revenue grew 12% YoY to ₹28 crore.

    Concerns

    2
    • Ethylene Oxide (EO) supply constraints from Reliance

    • Delays in new capacity commercialization

    Key financials

    Metrics

    6

    Periods

    3

    Headline

    4
    • Revenue
      ₹512.7 Cr
      YoY+10.5%
    • EBITDA
      ₹64.8 Cr
    • EBITDA Margin
      12.6%
    • PAT
      ₹31.7 Cr

    Q3

    1
    • Exports
      ₹156 Cr

    9M

    1
    • Exports
      ₹405 Cr
      YoY+28.0%

    Segment breakdown

    • HPPC₹390 Cr54.7%
    • Textile Specialty Chemical₹95 Cr13.3%
    • AHN₹28 Cr3.9%
    • Buzil Rossari (Rossari Professional) (9M)₹200 Cr28.1%
    Donut· Share of Revenue

    Guidance & targets

    18
    CategoryTargetPriority
    Capacity
    New capacity commissioning
    phased manner in the coming months and some of them in Q1 of FY26
    High
    Capacity
    New capacity scale-up to full utilization
    3-3.5 years
    Medium
    Capacity
    Ethoxylation capacity addition
    about 30,000 tons
    High
    Capacity
    Ethoxylation capacity utilization timeline
    about 3 years or so
    Medium
    Capex
    New CAPEX asset turn at peak utilization
    3.5x-4x
    Medium
    Capex
    New CAPEX total amount spent
    about Rs. 140 crore
    High
    Revenue
    Buzil Rossari (Rossari Professional) revenue
    Rs. 250 crore plus
    High
    Revenue
    Buzil Rossari (Rossari Professional) revenue
    Rs. 450 – Rs. 500 crore
    High
    Revenue
    Bangladesh geography revenue
    Rs. 100-crore geography
    Medium
    Revenue
    Bangladesh monthly sales
    Rs. 6 Rs. 7 crore
    Medium
    Revenue
    New capacity revenue contribution
    start showing up
    Medium
    Revenue
    New CAPEX peak revenue potential
    Rs. 550 odd crore
    Medium
    Revenue
    Institutional cleaning business (Buzil Rossari) additional revenue from new CAPEX
    Rs. 200 crore
    Medium
    Profitability
    Buzil Rossari (Rossari Professional) EBITDA contribution
    start contributing to the EBITDA
    Medium
    Profitability
    PAT growth rate vs. revenue growth rate
    at least start growing the PAT at the rate of revenue growth
    Medium
    Headcount
    Employee cost / additions
    around the same number for next couple of quarters, rate of adding people slightly lesser than this year
    Medium
    Other
    Total expense (excluding employee benefit)
    around this range plus minus 10%
    Medium
    Export
    Export growth traction
    start seeing some good traction
    Medium

    Risks & concerns

    4
    RiskSeverity

    Ethylene Oxide (EO) supply constraints from Reliance

    Reliance has not confirmed when they will start supplying higher EO allocation, which is a constraint for Rossari's new capacity utilization.Management acknowledged

    high

    Delays in new capacity commercialization

    If EO capacities are delayed by a quarter or 6 months, plans for additional revenue and margins from new capacity could be slowed down.Management acknowledged

    high

    Low EBITDA contribution from Buzil Rossari (institutional cleaning)

    The institutional cleaning business is consumer-focused and currently has low EBITDA due to significant investments in people and infrastructure during its growth phase.Management acknowledged

    medium

    Slow growth in domestic Textile market

    The domestic Textile market is growing at a low single-digit rate (5-6%), requiring focus on exports for growth.Management acknowledged

    medium

    Q&A highlights

    3

    “Our major exports are to America, which includes Latin and South America, to Europe and also to Turkey. But now we are opening up geographies also in the Gulf area. Basically, I think geographies remain the same, but we are trying to add new customers and new segments in the businesses. In terms of HPPC, the surfactant business, which is our core business, continues to dominate over everything else.”

    Provides clarity on key export markets and the dominant product category driving export growth, which is a key focus area for the company.

    asked by Rohit Nagraj

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY25 Performance Overview and Export-Led Growth

    Rossari Biotech reported a resilient Q3 FY25, with consolidated revenues increasing by 10.5% YoY to ₹512.7 crore. All business segments contributed to growth, with HPPC at ₹390 crore (+9.6% YoY), Textile Specialty Chemicals at ₹95 crore (+14.5% YoY), and AHN at ₹28 crore (+12% YoY). Exports were a significant driver, registering 21% YoY growth in Q3 and 28% over the nine months, with Q3 export revenue reaching ₹156 crore.

    02

    Margin Dynamics and Cost Structure

    Gross margins improved by 137 basis points YoY, supported by a favorable product mix and operational efficiencies. However, EBITDA margins compressed to 12.6% (from 13.7% last year) due to higher expenses related to ongoing growth initiatives, capacity expansion, and investments in businesses in their growth phases, such as the institutional cleaning vertical. Employee costs increased with approximately 190 new hires YoY, with 120 in the institutional cleaning division alone.

    03

    Capacity Expansion and Ethoxylation Constraints

    The company's CAPEX projects, including 30,000 tons of ethoxylation capacity expansion at Unitop's Dahej facility and HPPC expansion, are progressing well and are expected to be commissioned in a phased manner, with some in Q1 FY26. The total CAPEX spent is about ₹140 crore, projected to yield ₹550 crore in peak revenue (4x asset turn). However, a critical risk remains the uncertainty of Ethylene Oxide (EO) supply from Reliance, which could delay the full utilization of new capacities and impact revenue and margin growth in FY26.

    04

    Buzil Rossari (Rossari Professional) Business Update

    The institutional cleaning business, Buzil Rossari (now Rossari Professional), achieved ₹200 crore in revenue in the first nine months, representing 50% YoY growth. Management aims for this business to reach over ₹250 crore by FY25 and ₹450-500 crore within two years. While currently operating at low EBITDA due to significant investments in expanding its offerings beyond pure chemicals to a complete hygiene solution, it is expected to start contributing positively to EBITDA once it reaches the ₹450-500 crore revenue mark.

    05

    Textile Business Recovery and Export Focus

    The Textile Specialty Chemicals business showed a strong uptick, primarily driven by exports, which grew about 14% YoY in Q3. Domestic textile growth remains modest at 5-6%. The company is strategically focusing on high-margin finishing chemicals and expanding its export footprint in geographies like Egypt, Turkey, North Africa, and Bangladesh, with a long-term target of making Bangladesh a ₹100 crore geography. New offices are being set up in Vietnam, Thailand, Turkey, and UAE to support this export push.

    06

    Future Outlook and Strategic Initiatives

    Rossari Biotech remains optimistic about sustained growth, driven by innovation, capacity enhancements, and global market expansion. New capacities are expected to start contributing to revenue from Q2 FY26, with full utilization anticipated in 3-3.5 years. The company is committed to leveraging strategic investments to unlock new opportunities and strengthen its market position, aiming for PAT growth to align with revenue growth in FY26, contingent on raw material availability.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.